Company Overview - Hologic, Inc. (HOLX) is a global medical technology company with a market cap of $16.8 billion, focusing on diagnostic products, medical imaging systems, and surgical solutions for women's health [1] - The company operates through four main segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, providing tools for early detection, diagnosis, and treatment [1] Stock Performance - Hologic is classified as a "large-cap" stock, valued at $10 billion or more [2] - The stock has experienced a marginal decline from its 52-week high of $75.75, but has risen slightly over the past three months, outperforming the Dow Jones Industrials Average, which saw a 2% drop [3] - Year-to-date, HOLX stock is up marginally, surpassing the Dow Jones' 2.2% decrease, and has increased 21% over the past 52 weeks compared to the Dow's 13% return [5] Recent Financial Results - Following its Q1 2026 results, Hologic's shares fell marginally, with adjusted EPS at $1.04 and revenue totaling $1.05 billion, both below expectations [7] - The company faced challenges including weakness in Diagnostics revenue, margin compression due to $15.3 million in tariff-related costs, and a lack of forward guidance due to a pending acquisition by Blackstone and TPG [7] Competitive Position - Hologic's stock performance has outpaced that of its rival, The Cooper Companies, Inc. (COO), which has seen a 13.2% decline year-to-date and an 11.2% decline over the past 52 weeks [8] - Despite Hologic's outperformance, analysts maintain a cautious outlook, with a consensus rating of "Hold" among 18 analysts and a mean price target of $75.58, indicating a marginal premium to current levels [8]

Group 1: Investment Performance - Sound Shore Management's Investor Class (SSHFX) and Institutional Class (SSHVX) delivered returns of 3.06% and 3.10% respectively in Q2 2025, underperforming the Russell 1000 Value Index at 3.79% and the S&P 500 at 10.94% [1] - The fund's 35-year annualized returns were 14.92% for SSHFX and 15.14% for SSHVX as of June 30, 2025, surpassing the Russell Value's 12.76% but trailing the S&P 500's 19.71% [1] Group 2: Hologic, Inc. Overview - Hologic, Inc. (NASDAQ:HOLX) is a medical instruments and supplies company focused on women's health, with a market capitalization of $14.57 billion and a share price of $65.50 as of September 10, 2025 [2] - The stock experienced a one-month return of -3.75% and a 52-week decline of 18.55% [2] Group 3: Regulatory Environment and Investment Strategy - Uncertainty regarding regulatory policies, including Medicaid reimbursement and pharmaceutical pricing, has negatively impacted healthcare holdings, including Hologic, Inc. [3] - Sound Shore Management took advantage of price dislocation during market drops to increase its position in Hologic, Inc., which is valued at around 14 times earnings [3] Group 4: Hedge Fund Interest and Financial Performance - Hologic, Inc. was held by 47 hedge fund portfolios at the end of Q2 2025, an increase from 46 in the previous quarter [4] - The company reported revenue of $1.024 billion in fiscal Q3 2025, exceeding guidance [4]